DFDA

Rituximab with Hyper-CVAD/MA

Treatment for Burkitt Lymphoma

Typical Dosage: Complex multi-drug, dose-intensive regimen, intravenously in inpatient setting

Effectiveness
87%
Safety Score
25%
Clinical Trials
50
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Complex multi-drug, dose-intensive regimen, intravenously in inpatient setting
Time to Effect
Within weeks of starting cycles
Treatment Duration
4-6 months (6-8 cycles)
Evidence Quality
HIGH
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$80,000
Side Effect Mgmt:$70,000
Total Annual:$300,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
5
Outcome-Based Costs
Cost per Responder
$333,333.33
Cost per Remission
$352,941.18
Rituximab with Hyper-CVAD/MA Outcomes

for Burkitt Lymphoma

Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+95%
Febrile Neutropenia/Infection
+60%
Mucositis/Stomatitis
+60%
Nausea/Vomiting
+80%
Fatigue
+85%
Alopecia
+90%
Neurotoxicity (Vincristine-induced)
+40%
Cardiotoxicity (Doxorubicin-induced)
+10%

Sources:

researchgate.net
nih.gov
e-century.us

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov